Content of this page is provided and copyrighted by the exhibitor. Click follow exhibitor to be notified of new content.
Copyright © 2018 Dash Genomics, Inc.
Dash Genomics (www.dashgenomics.com) has partnered with UCSF and UCSD scientists to offer a new model to understand individual risk of Alzheimer’s disease beyond only the APOE gene, as a function of age and genetic information. Dash Genomics has now made this state-of-the-art algorithm available to anyone with 23andMe or Ancestry.com DNA data.
The personalized Alzheimer’s risk analysis is available from Dash Genomics for $149 but is currently available at a special introductory price of $99.
The proprietary algorithm used by Dash Genomics was developed by HealthLytix, a precision health company in San Diego, and is based on cutting-edge research from UC San Diego and UC San Francisco. The research looks at age-specific risk of developing Alzheimer’s disease based on genetic markers that have never been used before for estimating risk. The model looks at the similarities between genetic profile and the average risk in the group analyzed in the research.
Read more about:
Insight into your personalized Alzheimer’s Disease risk
- Simple Process: At www.dashgenomics.com, upload your genomic raw data from 23andme or Ancestry.com, and get your report in seconds
- Grounded in Science: The analysis is rooted in cutting-edge scientific research from UC San Francisco and UC San Diego
- In-depth Alzheimer's Risk Analysis:
- Dash Genomics Personal Risk Analysis is the only analysis on the market that goes beyond the APOE gene. Sample report available here.
- Cumulative Risk -- the risk of onset of Alzheimer's by a certain age
- Instantaneous Risk -- the risk of onset of Alzheimer's within a certain year of age
- Risk over the next 5 years (for those over 65)
- AZ50 age -- the age your cumulative risk rises above 50%
- Polygenic Hazard Score (PHS) percentile -- Compare your estimated risk profile to the general population
Dash Genomics' analysis is for informational purposes only, has not been validated for clinical use, and is not meant to be used for diagnostic or medical purposes.
The Virtual Exhibit Hall is paid advertising. FBRI has not been involved in the preparation, adoption or editing of Third Party Content. While FBRI makes every attempt to provide accurate and timely information to serve the needs of users, neither FBRI nor the Third Party Content Providers guarantee its accuracy, timeliness, completeness or usefulness, and are not responsible or liable for any such content, including any advertising, products, or other materials on or available from third party sites. FBRI and the Third Party Content Providers specifically disclaim any responsibility for Content available on the Site. The use of the Site and the Content, including Third Party Content, is at your own risk.